CollPlant (CLGN) 6-K: Mayo Clinic unveils 3D bioprinted human skin

Accepted by SEC EDGAR 10/16/2025 - 12:00 AM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

CollPlant Biotechnologies (CLGN) filed a Form 6-K noting it issued a press release on October 16, 2025 titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.” The notice highlights Mayo Clinic researchers’ work and references CollPlant’s rhCollagen-based BioInk. No additional operational or financial details are included in this filing excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CLGN disclose in this Form 6-K?

It disclosed the issuance of a press release titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.”

When was the press release issued by CollPlant (CLGN)?

October 16, 2025.

Who is credited with developing the 3D bioprinted human skin model?

Mayo Clinic researchers, as stated in the press release title.

What technology from CollPlant is referenced in the announcement?

CollPlant’s rhCollagen-based BioInk.

What is the form type of this submission?

Form 6-K.

What is CollPlant’s full company name?

CollPlant Biotechnologies Ltd.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On October 16, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk”.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1

Press Release, dated October 16, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.

Date: October 16, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

Source: View Original Filing on SEC EDGAR